MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
News & Events
January 3, 2017
MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi
December 2, 2016
MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
December 1, 2016
MyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer
November 11, 2016
MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients